Meshy, an AI-powered 3D content platform, today announced continued expansion of its AI-assisted 3D creation workflow to help ...

The Osteosarcoma market presents opportunities in developing novel therapies, with over 25 companies working on 32+ drugs in the pipeline. There is strong focus on Phase III products like HS-20093, ...

Archer Aviation is executing Phase 4 FAA certification, with commercialization likely by 2028 and strong upside potential. Read more on ACHR stock here.

More than 100 Japanese firms now operate global capability centres in India as focus shifts to AI, engineering, R&D and ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

Learn about JellyFil, including its latest company news, product developments, business updates, and official announcements.

GeneTAC® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 ...

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda 1 (pembrolizumab), have met their primary endpoints.

Abstract recently submitted in anticipation of initial data analysis ahead of ESCCompany expects to report topline LEVEL results in AugustCHAPEL ...

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA's decision follows positive Phase 1 results for GT-02287 in both healthy ...

LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive ...